Discontinued — last reported Q4 '19
Corvex Antidilutive Securities Excluded from EPS increased by 8975.8% to 70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12381.8%, from 560.6K to 70M.
A high number indicates a significant volume of equity-based awards that are currently priced above the market, posing less immediate dilution risk.
The count of potential common shares from stock options, warrants, or convertible instruments that are excluded from the...
Standard disclosure in financial footnotes for companies with complex equity compensation structures.
jnj_antidilutive_securities_excluded_from_eps| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q1 '25 | Q2 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | 203.4K | 203.4K | 203.4K | 203.4K | 813.7K | 3.3M | 560.6K | 4.1M | 771K | 70M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +300.0% | +302.2% | -82.9% | +637.2% | -81.3% | >999% |
| YoY Change | — | — | — | — | +300.0% | >999% | -31.1% | +26.3% | — | >999% |